We work on a broad range of product types from viral vectors to nucleic acid or recombinant proteins to inactivated bacterial vaccines.
Our novel flexible manufacturing approach means we will work with you to install new platform capabilities to meet your needs.
We can produce the product at small scales, from less than 1 litre to 50 litres of culture, or at larger 200 litre or 1,000 litre scales. At every stage we will look at the conditions to grow cells most effectively.
Once the subsequent steps are complete, we will purify the product, ready for fill–finish at our facility or to be transferred to another of your partners. We will actively support technology transfer at every stage of the process.
Meet the expert
Team Leader (Downstream)
Gaurav has a Ph.D. in Virology and Vaccinology with 17+ years of industrial and academic experience. He has delivered several vaccine projects including live viral, subunit, VLPs, Inactivated, and viral vectored for clinical trials phase 1, 2, 3, and commercial production. He has successfully progressed more than 10 vaccines (live viral vaccines and influenza vaccines) to final market authorization after passing all clinical trials. Gaurav’s most recent work on malaria has encompassed managing multiple GMP process developments, tech transfer for clinical trials manufacturing, and also contributing to the bioprocess development for Oxford/Astrazeneca COVID-19 vaccine.